No Data
No Data
Sernova Announces Additional Patient Insulin Independent and Cohort 2 Enrollment Complete in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes
To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non-diabetic range (HbA1c 6.5%);
Sernova Appoints Jonathan Rigby to Its Board of Directors
Sernova Corp. AGM Elects Board, Advances Therapies
Sernova Announces AGM Voting Results
Sernova Provides Organizational Update
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for Its Board of Directors